**MTN-032**

**Phase 2 Female IDI Debriefing Report**

***Purpose:***

1. *Provide a general overview of the content discussed in the interview,*
2. *Record information that might not be reported otherwise (i.e. context and meaning of behaviors; e.g. non-verbal cues, emotional states, body language, etc.)*

***Instructions:***

*This report is to be completed by the interviewer on the same day as the interview and forwarded to RTI within one week of interview completion. The note-taker should be consulted to verify content and add detail where applicable. This report should be uploaded to the FTP site as a Word document. Any relevant visual tools (i.e. over-time tool and opinion tool) should be uploaded at the same time as the debrief report.*

|  |  |
| --- | --- |
| **Basic IDI Information:** | |
| **PTID**:  **Interview Date**:  **Recruitment Drug Level Subgroup**:  **CRS/CTU**:  **Venue**:  **Interview length**: | **Interviewer**:  **Note-taker**:  **Person Completing Form**:  **Site Person Reviewing Form**:  **Date of DR Completion**: |
| **Debriefing Summary:** | |
| 1. **What are your general impressions from the IDI today?** (*Describe in detail your subjective impressions of how the participant behaved, their emotional reactions [excited, sad, laughed, bored, confused, disappointed etc.], and any other important information about the context, non-verbal communication and experience that might not be included on the transcript)*   **1a. What did you think about the length of the interview?**  Too long  Just right  Too short  **Comments on interview length (if needed)**:   1. **Themes or ideas discussed** *(Describe in detail the most important ideas discussed within each of the interview main topic areas and any important issues that were raised.)*     1. **Motivation for joining HOPE and effects of participation** *(Include details about reasons for joining HOPE, whether she was influenced more from the ring or the study benefits, how HOPE affected her emotionally or socially, etc.)***:**    2. **Understanding of how the ring works to protect against HIV** *(Include details on how the participant thinks she needed to use ring in comparison to what was told to her, her need to be protected all the time or not, and how she thinks the ring works in her body)***:**    3. **Participant’s response to the drug level results discussion** *(Record details about her feelings of these results [i.e. match how she used the ring; whether she trusts the method used to test the ring] that expand upon their reaction recorded on the PSF; any non-adherence to the ring including duration of time ring was out)***:**    4. **Effect on sexual activity and disclosure with partner *(****Record details on how the ring affected sexual life, comfort with telling partners about the ring, partner knowledge and opinion of ring if applicable)***:**    5. **Barriers and facilitators of ring use** *(Include details such as challenges to consistent use, motivations for use)***:**    6. **Participation in clinic events** *(If applicable, include type of events attended, preference for event types and topics)****:***    7. **Opinion Tool PROCESS** (*Describe briefly how this exercise went, any challenges experienced for you or for the participant, and any suggestions for improving the activity for future interviews*)**:**    8. **Opinion Tool Data** *(Be sure to describe opinions of vaginal ring including details about what was discussed during the opinion tool activity)***:**    9. **HIV worries and HIV protection** *(Include details on how worried participant was about HIV during HOPE and plans for how to protect herself in the future)***:**    10. **Future ring use** *(Record details on whether participant or others might be interested in using ring in the future, who is most likely to be interested in it, and what someone should know before using the ring)***:** 2. **Were there any other important issues, unexpected or unanticipated findings?** *(Record anything unexpected, unanticipated, or new that was learned from this IDI; positive or negative mentions of staff/clinic; other important issues)***:**      1. **Were there any potential Social Harms (SH), or Protocol Deviations (PD) mentioned in the interview today**?   No  Yes *(Record what was mentioned during the interview and the action taken to report the AE/SH/PD or refer the participant, if applicable.)* | |